Leap Therapeutics reported that while the study showed some activity in biomarker populations, it failed to produce a decisive positive signal. The study's data suggested a high level of ...
Shares of Leap Therapeutics, Inc. nosedived more than 70% to an all-time low on Tuesday, making them the top loser across U.S. exchanges. The sharp drop — Leap’s worst intraday fall ever ...
Leap Therapeutics (NASDAQ:LPTX) fell ~12% on Wednesday as Baird downgraded the stock after the biotech said its lead candidate, sirexatamab, generated disappointing data in a mid-stage trial for ...
Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data ...
Leap Therapeutics Halts Sirexatamab Combo Therapy For Gastric Cancer ON Unclear Positive Signal, Stock Crashes Leap Therapeutics' Phase 2 data shows sirexatamab improves ORR in colorectal cancer.
Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...
On Wednesday, H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock rating from Buy to Neutral. The downgrade has intensified ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...